Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Sponsor: Oncology Specialists, S.C.
Terminated
Study terminated due to slow acrual
Other terminated trials from Oncology Specialists, S.C.
More terminations from Oncology Specialists, S.C.
Listed as NCT01078922, this PHASE2 trial focuses on Non-Hodgkin Lymphomas and remains terminated or withdrawn. Sponsored by Oncology Specialists, S.C., it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oncology Specialists, S.C.
- University of Illinois at Chicago
For direct contact, visit the study record on ClinicalTrials.gov .